Dry vs. Wet Macular Degeneration: How to Tell the Difference

If you or someone you love has been told they have “macular degeneration,” one of the first questions that usually comes up is, “Is it dry or wet?” The terms can sound confusing—and even a little alarming—but understanding the difference is one of the most important steps in protecting your vision. As a retina specialist, I often see patients feel anxious simply because no one has clearly explained what’s happening inside their eyes. The good news is that modern imaging, especially OCT scans, allows us to see macular degeneration with remarkable clarity and guide treatment with precision.

Understanding the differences between dry and wet macular degeneration is crucial for early diagnosis and treatment. This infographic highlights key symptoms, such as the slow progression and wavy or blurry vision in dry AMD, versus the rapid vision loss and leaking vessels in wet AMD. It also emphasizes the importance of OCT scans for clear imaging and early treatment.

Macular degeneration, more formally called age-related macular degeneration (AMD), affects the macula, the central part of the retina responsible for sharp, detailed vision. This is the part of your vision you rely on for reading, recognizing faces, driving, and using digital devices. AMD does not cause total blindness, but it can significantly impact quality of life if it progresses unchecked. The condition exists in two main forms—dry and wet—and while they are related, they behave very differently.

Dry macular degeneration is the more common form, accounting for the majority of AMD cases. It develops slowly over time and is characterized by the buildup of tiny deposits called drusen beneath the retina. These deposits can interfere with how retinal cells receive nutrients and remove waste. On an OCT scan, dry AMD often appears as subtle irregularities or thinning of the retinal layers, along with elevations caused by drusen. There is usually no fluid leaking in dry AMD, which is an important distinction. Many people with early dry AMD may not notice symptoms at all, while others may experience mild blurring or difficulty seeing in low light. Because progression is gradual, dry AMD is often managed with careful monitoring, lifestyle modifications, and, in certain cases, specific vitamin formulations shown to slow progression.

Wet macular degeneration, while less common, is more aggressive and can cause rapid vision loss if not treated promptly. It occurs when abnormal blood vessels grow beneath the retina and begin to leak fluid or blood. This leakage disrupts the normal retinal structure and damages the cells responsible for central vision. On OCT imaging, wet AMD is usually unmistakable. The scan often shows fluid pockets within or beneath the retina, swelling, and sometimes scarring. Patients with wet AMD frequently notice sudden distortion, wavy lines, dark spots in the center of vision, or a rapid decline in visual clarity. The urgency here cannot be overstated, because timely treatment can often stabilize or even improve vision.

This is where OCT imaging becomes especially powerful. Optical coherence tomography is a noninvasive scan that works a bit like an optical ultrasound, using light instead of sound. It creates cross-sectional images of the retina, allowing doctors to see its layers in extraordinary detail. For patients, the test is quick, painless, and doesn’t require injections or contact with the eye. For doctors, it provides critical information about whether fluid is present, how thick the retina is, and how the disease is changing over time. By keeping OCT images clean and focused—without unnecessary visual clutter—we can clearly explain what’s happening and make informed decisions together.

Treatment approaches differ significantly between dry and wet AMD. Currently, there is no cure for dry AMD, but progression can often be slowed. Nutritional supplementation based on large clinical trials, along with managing risk factors like smoking, blood pressure, and cardiovascular health, plays an important role. Regular monitoring is essential, because dry AMD can sometimes convert to wet AMD, which requires immediate attention. Wet AMD, on the other hand, is commonly treated with medications injected into the eye that block abnormal blood vessel growth and leakage. These treatments, known as anti-VEGF therapy, have transformed outcomes for patients and are guided closely by OCT findings to ensure the retina stays dry and stable.

For patients, one of the most practical takeaways is the importance of early detection and consistency. Subtle changes in vision should never be ignored, especially if straight lines begin to look wavy or blurred. Home monitoring tools, like an Amsler grid, can be helpful, but they do not replace regular eye exams and imaging. If you have been diagnosed with dry AMD, staying engaged with follow-up visits allows us to catch changes early. If you have wet AMD, adhering to your treatment schedule can make a meaningful difference in long-term vision.

Understanding whether macular degeneration is dry or wet is not just about labels—it’s about knowing what to watch for, how urgently to act, and what tools we have to protect your sight. With clear OCT imaging and a personalized approach, patients are no longer left guessing. Instead, they become informed partners in preserving their vision for years to come.

Connect with Us

Website: www.southbayretina.com

Phone: (408) 294-3534

Serving: San Jose, Cupertino, and the greater South Bay Area

YouTube: youtube.com/@NarainEye

Instagram: @south_bay_retina

Facebook: @narain1

TikTok: @southbayretina

Podbean: southbayretinamedia.podbean.com

References

1. Age-Related Eye Disease Study Research Group. (2001). A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Archives of Ophthalmology, 119(10), 1417–1436. https://pubmed.ncbi.nlm.nih.gov/11594942/

2. Ferris, F. L., Wilkinson, C. P., Bird, A., Chakravarthy, U., Chew, E., Csaky, K., & Sadda, S. R. (2013). Clinical classification of age-related macular degeneration. Ophthalmology, 120(4), 844–851. https://pubmed.ncbi.nlm.nih.gov/23332590/

3. National Eye Institute. (2023). Age-related macular degeneration (AMD). https://www.nei.nih.gov/learn-about-eye-health/eye-conditions-and-diseases/age-related-macular-degeneration

4. Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006). Ranibizumab for neovascular age-related macular degeneration. New England Journal of Medicine, 355(14), 1419–1431. https://pubmed.ncbi.nlm.nih.gov/17021318/

WATCH THE FULL EPISODE'S HERE:

https://www.youtube.com/watch?v=OMrr10x5-KQ

LISTEN TO THE PODCAST EPISODES: